Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration
Rahway-based Merck announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748 (also known as Tiespectus, EYE201). It is a novel investigational bispecific antibody t...